Melanoma Research

Papers
(The H4-Index of Melanoma Research is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients41
Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma41
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)37
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)27
Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature23
Stage-specific incidence trends of melanoma in an English region, 1996–2015: longitudinal analyses of population-based data23
Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas19
Impact of COVID-19 on melanoma diagnosis17
The molecular profile of mucosal melanoma17
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials14
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)14
Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases13
Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases13
0.029102802276611